AEON Biopharma, Inc.
AEON- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001837607
In the last 90 days, AEON Biopharma, Inc. insiders filed 3 open-market purchases and 0 sales; 28 institutions reported holding it in 13F filings for Q3 2026, worth $18.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $10.3M
- Insider buysLast 90 days, $57.1K in total
- 3
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +6 vs. previous quarter
- 28
- 13F valueReported value at the end of Q3 2026
- $18.7M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$39.2M
- −193.4% year over year
- Free cash flow, FY2025
- -$17.3M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.66M
- Shares sold short
- Change
- −589.2K
- −18.1% vs. previous
- Days to cover
- 6.40
- At average daily volume
Superinvestors holding AEON, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding AEON at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by AEON Biopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 20, 2026 (view filing)5:11 PM ET | Nov 20 | Same day | Wilson Alexander BlairCLO, CSO and Corp Secretary | PPurchaseClass A Common Stock | +135.7K | $0.1288 | +$17.5K | +6.2%2.32M after | |
| Nov 20, 2026 (view filing)5:10 PM ET | Nov 19 | 1 day | Sy JenniferChief Accounting Officer | PPurchaseClass A Common Stock | +153.8K | $0.1299 | +$20.0K | +10.2%1.66M after | |
| Nov 20, 2026 (view filing)5:08 PM ET | Nov 19 | 1 day | Bancroft Robert E.President and CEO | PPurchaseClass A Common Stock | +152.3K | $0.1286 | +$19.6K | +4.8%3.33M after | |
| Aug 21, 2026 (view filing)7:41 PM ET | Aug 19 | 2 days | Lynch Timothy P10% Owner | PPurchaseClass A Common Stock | +1.15M | $0.2117 | +$243.5K | +21.5%6.50M after | |
| May 23, 2025 (view filing)4:46 PM ET | May 21 | 2 days | Fischer JostDirector | PPurchaseClass A Common Stock | +60.0K | $0.4875 | +$29.3K | +29.0%266.8K after | |
| May 21, 2025 (view filing) | May 19-20 | 2 days | Fischer JostDirector | PPurchaseClass A Common Stock | +110.0K | $0.5055 | +$55.6K | +113.7%206.8K after | 2 lots |
| Aug 14, 2023 (view filing) | Aug 11 | 3 days | Strathspey Crown Holdings Group, LLC10% Owner | SSaleClass A Common Stock | −7.38M | $10.00 | −$73.8M | −78.4%2.03M after |
Top 10 13F holders, Q3 2026
See all 28 holdersThe largest institutional positions in AEON Biopharma, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Dauntless Investment Group, LLC | 51,734,490 | $15.5M | 28.43% | +39,244,336+314.2% | Added |
| Nantahala Capital Management, LLC | 4,400,000 | $1.30M | 0.07% | +4,400,000 | New |
| Ikarian Capital, LLC | 2,203,406 | $661.0K | 0.13% | +2,203,406 | New |
| Stonepine Capital Management, LLC | 2,125,748 | $637.7K | 0.53% | +2,125,748 | New |
| Boothbay Fund Management, LLC | 703,865 | $211.2K | 0.00% | +703,865 | New |
| DG Capital Management, LLC | 259,146 | $77.7K | 0.03% | +259,146 | New |
| Jane Street Group, LLC | 249,762 | $74.9K | 0.00% | +249,762 | New |
| Vanguard Fiduciary Trust Co | 214,725 | $64.4K | 0.00% | +201,012+1,465.8% | Added |
| Geode Capital Management, LLC | 95,311 | $28.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 90,529 | $27.2K | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of AEON
See all 10 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of AEON Biopharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Daewoong Co., Ltd | 13D | 49.99%12.0M shares | +49.09 ppfrom 0.90% | Jul 28, 20233 filings | Jan 29, 2026 | SEC |
| Daewoong Co., Ltd | 13D/A | 30.60%23.2M shares | – | Nov 10, 20261 filing | Nov 10, 2026 | SEC |
| Lynch Timothy P | 13G | 13.00%6.50M shares | New | Aug 21, 20261 filing | Aug 21, 2026 | SEC |
| Nantahala Capital Management, LLC | 13G | 9.99%5.05M shares | New | Nov 13, 20261 filing | Nov 13, 2026 | SEC |
| Ikarian Capital, LLC | 13G | 9.90%7.36M shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |